BIOXYTRAN, INC (74)

Browse by Contract Category

Contracts

Modification/Amendment to Officers Employment Contract, dated October 28, 2022 (Filed With SEC on November 14, 2022)
Form of Subscription Agreement (Filed With SEC on August 17, 2022)
Official USPTO Notice of Publication under 12(A) for the Trademark ProLectin (Filed With SEC on June 10, 2022)
Approval of International Patent WO2022/099061 - Polysaccharides for IV Administration that Treat SARS-CoV-2 Infections, dated May 12, 2022 (Filed With SEC on June 10, 2022)
Approval of International Patent WO2022/099052 - Polysaccharides for Use in Treating Sars-Cov-2 Infections, dated May 12, 2022 (Filed With SEC on June 10, 2022)
Joint Venture Agreement between Bioxytran and Pharmalectin Partners, LLC, dated November 15, 2020 (Filed With SEC on April 9, 2021)
Form of Note Purchase Agreement, dated January 5, 2022 (Filed With SEC on January 14, 2022)
Form of Convertible Note, dated January 5, 2022 (Filed With SEC on January 14, 2022)
Form of Private Placement Memorandum dated September 17, 2021 (Filed With SEC on November 17, 2021)
Form of Private Placement Memorandum dated February 26, 2021 (Filed With SEC on November 17, 2021)
Form of Subsidiary Option dated June 4, 2021 (Filed With SEC on November 17, 2021)
Form of Warrant dated June 4, 2021 (Filed With SEC on November 17, 2021)
2017 Employee, Director and Consultant Stock Plan (Subsidiary), adopted by the Board of Directors on October 5, 2017 (Filed With SEC on June 24, 2021)
2021 Employee, Director and Consultant Stock Plan, adopted by the Board of Directors on January 19, 2021 (Filed With SEC on June 24, 2021)
License Agreement between Pharmalectin, Inc. and NDPD Pharma, Inc. dated May 2, 2021 (Filed With SEC on June 24, 2021)
License Agreement between Bioxytran, Inc. and Pharmalectin, Inc. dated May 5, 2020 (Filed With SEC on June 24, 2021)
Form of Convertible Note Agreement between Note Holders and Bioxytran, Inc., dated May 2 and 3, 2021 (Filed With SEC on June 7, 2021)
Form of Employment Agreement of Mike Sheikh, dated May 1, 2020 (Filed With SEC on April 9, 2021)
8% Convertible Debenture of Bioxytran, Inc. to Power Up Lending Group LLC in the Principal Amount of $64,900 dated March 18, 2020 (Filed With SEC on March 26, 2020)
Securities Purchase Agreement between Power Up Lending Group LLC and Bioxytran, Inc., dated March 18, 2020 (Filed With SEC on March 26, 2020)
Amendment #1 to Securities Purchase Agreement between Auctus Fund LLC and Bioxytran, Inc., dated February 25, 2019 (Filed With SEC on March 12, 2020)
Amendment #1 to Securities Purchase Agreement between Auctus Fund LLC and Bioxytran, Inc., dated October 24, 2018 (Filed With SEC on March 12, 2020)
Securities Purchase Agreement between Crown Bridge Partners, LLC and Bioxytran, Inc., dated October 30, 2019 (Filed With SEC on February 26, 2020)
Securities Purchase Agreement between Power Up Lending Group LLC and Bioxytran, Inc., dated January 18, 2020 (Filed With SEC on February 26, 2020)
8% Convertible Debenture of Bioxytran, Inc. to Power Up Lending Group LLC in the Principal Amount of $56,600 dated January 18, 2020 (Filed With SEC on February 26, 2020)
4% Convertible Note of Bioxytran, Inc. to Crown Bridge Partners, LLC in the Principal Amount of $55,000 dated October 30, 2019 (Filed With SEC on February 26, 2020)
Warrant to Purchase 22,000 shares of Common Stock of Bioxytran (Filed With SEC on February 26, 2020)
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran (Filed With SEC on January 15, 2020)
4% Convertible Note of Bioxytran, Inc. to EMA Financial LLC. in the Principal Amount of $125,000 dated January 10, 2020 (Filed With SEC on January 15, 2020)
Securities Purchase Agreement between EMA Financial LLC and Bioxytran, Inc., dated January 10, 2020 (Filed With SEC on January 15, 2020)
8% Convertible Note of Bioxytran, Inc. to Power Up Lending Group in the Principal Amount of $54,600 dated December 30, 2019 (Filed With SEC on January 6, 2020)
Securities Purchase Agreement between Power Up Lending Group and Bioxytran, Inc., dated December 30, 2019 (Filed With SEC on January 6, 2020)
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran (Filed With SEC on November 25, 2019)
4% Convertible Note of Bioxytran, Inc. to FirstFire Global Opportunities Fund, LLC. in the Principal Amount of $125,000 dated November 20, 2019 (Filed With SEC on November 25, 2019)
Securities Purchase Agreement between FirstFire Global Opportunities Fund, LLC and Bioxytran, Inc., dated November 20, 2019 (Filed With SEC on November 25, 2019)
Form of Letter Agreement between FON Consulting, LLC and Bioxytran, Inc. dated November 11, 2019 (Filed With SEC on November 12, 2019)
Form of Warrant to Purchase 50,000 shares of Common Stock of Bioxytran (Filed With SEC on November 12, 2019)
Form of Securities Purchase Agreement between GS Capital Partners, LLC and Bioxytran, Inc., dated No ember 7, 2019 (Filed With SEC on November 12, 2019)
Form of 4% Convertible Note of Bioxytran, Inc. to GS Capital Partners, LLC. in the Principal Amount of $125,000 dated November 7, 2019 (Filed With SEC on November 12, 2019)
8% Convertible Note of Bioxytran, Inc. to Tangiers Global, LLC in the Principal Amount of $106,300 dated October 23, 2019 (Filed With SEC on November 5, 2019)
Securities Purchase Agreement between Peak One Opportunity Fund, L.P. and Bioxytran, Inc., dated October 22, 2019 (Filed With SEC on November 5, 2019)
8% Convertible Note of Bioxytran, Inc. to PowerUp Lending Group Ltd. in the Principal Amount of $106,000 dated October 21, 2019 (Filed With SEC on November 5, 2019)
Securities Purchase Agreement between PowerUp Lending Group Ltd. and Bioxytran, Inc., dated October 21, 2019 (Filed With SEC on November 5, 2019)
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran (Filed With SEC on November 5, 2019)
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran (Filed With SEC on November 5, 2019)
Convertible Debenture of Bioxytran, Inc. to Peak One Opportunity Fund, L.P. in the Principal Amount of $120,000 dated October 22, 2019 (Filed With SEC on November 5, 2019)
8% Convertible Note of Bioxytran, Inc. to PowerUp Lending Group Ltd. in the Principal Amount of $106,000 dated October 21, 2019 (Filed With SEC on October 28, 2019)
Securities Purchase Agreement between PowerUp Lending Group Ltd. and Bioxytran, Inc., dated October 21, 2019 (Filed With SEC on October 28, 2019)
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran (Filed With SEC on October 28, 2019)
8% Convertible Note of Bioxytran, Inc. to Tangiers Global, LLC in the Principal Amount of $106,300 dated October 23, 2019 (Filed With SEC on October 28, 2019)
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran (Filed With SEC on October 28, 2019)
8% Convertible Debenture of Bioxytran, Inc. to Peak One Opportunity Fund, L.P. in the Principal Amount of $120,000 dated October 22, 2019 (Filed With SEC on October 28, 2019)
Securities Purchase Agreement between Peak One Opportunity Fund, L.P. and Bioxytran, Inc., dated October 22, 2019 (Filed With SEC on October 28, 2019)
Form of Advisory Board Agreement between Bioxytran, Inc. and Jonathan Jensen Dated September 13, 2019 (Filed With SEC on September 13, 2019)
Form of Advisory Board Agreement between Bioxytran, Inc. and Patrick Huddie dated September 13, 2019 (Filed With SEC on September 13, 2019)
Form of Advisory Board Agreement between Bioxytran, Inc. and Cynthia Tsai effective July 16, 2019 (Filed With SEC on August 1, 2019)
Form of Advisory Board Agreement between Bioxytran, Inc. and Jonathan Barkman effective July 15, 2019 (Filed With SEC on August 1, 2019)
Form of Advisory Board Agreement between Bioxytran, Inc. and Steven Aust dated June 11, 2019 (Filed With SEC on June 12, 2019)
Scientific Advisory Board Agreement between Bioxytran, Inc. and Asclepius LLC dated May 1, 2019 (Filed With SEC on May 6, 2019)
Investor Relations Agreement between Bioxytran, Inc. and Resources Unlimited NW LLC. dated April 22, 2019 (Filed With SEC on April 26, 2019)
License Agreement between Bioxytran, Inc. and MDX Lifesciences, Inc. dated April 4, 2019 (Filed With SEC on April 5, 2019)
Form of Securities Purchase Agreement between U.S. Rare Earth Minerals, Inc. and Auctus Fund, LLC, dated February 25, 2019 (Filed With SEC on March 1, 2019)
Form of Warrant of dated February 25, 2019 (Filed With SEC on March 1, 2019)
Form of Registration Rights Agreement between U.S. Rare Earth Minerals, Inc. and Auctus Fund, LLC, dated February 25, 2019 (Filed With SEC on March 1, 2019)
Form of Security Agreement dated February 25, 2019, between U.S. Rare Earth Minerals, Inc., and Auctus Fund, LLC, dated February 25, 2019 (Filed With SEC on March 1, 2019)
Form of $250,000 Senior Secured Promissory Note, dated February 25, 2019, of U.S. Rare Earth Minerals, Inc. and Auctus Fund, LLC, dated February 25, 2019 (Filed With SEC on March 1, 2019)
Form of Common Stock Certificate (Filed With SEC on February 1, 2019)
Form of Employment Agreement of David Platt (Filed With SEC on February 1, 2019)
Form of Employment Agreement of Ola Soderquist (Filed With SEC on February 1, 2019)
Form of Public Offering Subscription Agreement (Filed With SEC on February 1, 2019)
Form of Public Offering Subscription Agreement (Filed With SEC on January 30, 2019)
Form of Employment Agreement of Ola Soderquist (Filed With SEC on January 30, 2019)
Form of Employment Agreement of David Platt (Filed With SEC on January 30, 2019)
Form of Common Stock Certificate (Filed With SEC on January 30, 2019)